T1	Participants 83 111	chronic hepatitis B patients
T2	Participants 191 239	chronic hepatitis B patients with liver fibrosis
T3	Participants 249 300	57 chronic hepatitis B patients with liver fibrosis
T4	Participants 340 476	45 cases in KGQG group were treated by KGQG and routine medications; 12 cases in control group were treated by routine medications only.
T5	Participants 561 572	57 patients
T6	Participants 940 986	liver fibrosis in chronic hepatitis B patients
